{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D. ","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/acba852b\"></iframe>","width":"100%","height":180,"duration":741,"description":"Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.\n(01:14)\nCould you give us a brief overview of this assay?\n \n(02:06)\nCan you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?\n \n(04:00)\nWhen is this test typically ordered for transplant patients? Is it used throughout their treatment?\n \n(06:56)\nCould an immunocompromised person be unknowingly infected?\n \n(07:31)\nIs our quantitative method approved for pediatric patients?\n \n(08:00)\nHow are the test results used to treat patients?\n\n(10:36)\nWhat other infections might providers consider alongside adeovirus?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}